Common Contracts
3 similar Underwriting Agreement contracts by Trinity Capital Inc., Arcturus Therapeutics Holdings Inc.
TRINITY CAPITAL INC. UNDERWRITING AGREEMENT 5,190,312 SHARES OF COMMON STOCKUnderwriting Agreement • August 8th, 2023 • Trinity Capital Inc. • New York
Pursuant to the terms and conditions of this Underwriting Agreement (this “Agreement”), Trinity Capital Inc., a Maryland corporation (the “Company”) proposes to sell to you, UBS Securities LLC (“UBS”), Morgan Stanley & Co. LLC (“Morgan Stanley”), Keefe, Bruyette & Woods, Inc. (“KBW”), RBC Capital Markets, LLC (“RBC”) and Wells Fargo Securities, LLC (“Wells Fargo”) and each of the other underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 8 hereof), for whom UBS, Morgan Stanley, KBW, RBC and Wells Fargo are acting as representatives (in such capacity, the Representatives”), 5,190,312 shares (the “Initial Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The Company also proposes to grant to the Underwriters the option described in Section 1(b) hereof to purchase up to 778,546 additional shares of Common Stock from the Company (the “Opt
TRINITY CAPITAL INC. UNDERWRITING AGREEMENT 3,587,736 SHARES OF COMMON STOCKUnderwriting Agreement • August 18th, 2022 • Trinity Capital Inc. • New York
Pursuant to the terms and conditions of this Underwriting Agreement (this “Agreement”), Trinity Capital Inc., a Maryland corporation (the “Company”) proposes to sell to you, Keefe, Bruyette & Woods, Inc. (“KBW”), Morgan Stanley & Co. LLC (“Morgan Stanley”), UBS Securities LLC (“UBS”) and Wells Fargo Securities, LLC (“Wells Fargo”), and each of the other underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 8 hereof), for whom KBW, Morgan Stanley, UBS and Wells Fargo are acting as representatives (in such capacity, the “Representatives”), 3,587,736 shares (the “Initial Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). The Company also proposes to grant to the Underwriters the option described in Section 1(b) hereof to purchase up to 538,160 additional shares of Common Stock from the Company (the “Option Shares” and together with the Ini
1,365,000 Shares of Common Stock Arcturus Therapeutics Holdings Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • December 8th, 2020 • Arcturus Therapeutics Holdings Inc. • Pharmaceutical preparations • New York
Arcturus Therapeutics Holdings Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 1,365,000 shares of its common stock, par value $0.001 per share (the “Common Stock”). The 1,365,000 shares of Common Stock to be sold by the Company are called the “Firm Shares.” The Company also proposes to issue and sell to the several Underwriters up to an additional 204,750 shares (the “Additional Shares”) of Common Stock at the option of the Underwriters as provided in Section 2(c) below. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares.” Piper Sandler & Co. (“Piper Sandler”), Guggenheim Securities, LLC (“Guggenheim”) and Wells Fargo Securities, LLC (“Wells Fargo”) are each acting as representative (the “Representatives”) o
